CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ:CERS) announced today that a subsidiary of the Company has entered into an agreement to supply the INTERCEPT Blood System for platelets to the largest group of blood centers of the German Red Cross (DRK), including the Frankfurt region. The three-year agreement calls for the DRK Baden-Württemberg - Hessen to implement the INTERCEPT platelet system upon its receipt of marketing authorization from the Paul Ehrlich Institute for INTERCEPT-treated platelets, the successful outcome of a hemovigilence study it will conduct, and acceptance by its customers of the INTERCEPT-treated platelet products. The Paul Ehrlich Institute has previously granted a similar marketing authorization to another German blood center.
